Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AC0676 |
Synonyms | |
Therapy Description |
AC0676 is a BTK degrader, with activity against wild-type and mutant BTK, which reduces downstream signaling and potentially inhibits tumor growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AC0676 | AC 0676|AC-0676|AC-676|AC 676|AC676 | BTK inhibitor 37 | AC0676 is a BTK degrader, with activity against wild-type and mutant BTK, which reduces downstream signaling and potentially inhibits tumor growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05780034 | Phase I | AC0676 | A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Recruiting | USA | 0 |